Conditions: Rheumatoid Arthritis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 356
Healthy volunteers: no

Brief summary:
The primary purpose of the protocol is to describe the pharmacokinetics of a single dose of Abatacept 125 mg in Rheumatoid Arthritis patients delivered via the autoinjector device or the approved prefilled syringe.

Detailed description:
SC=Subcutaneous

Arms:
arm 1: Abatacept 125 mg/syringe subcutaneously through autoinjector, one dose in 71 days arm 2: Abatacept 125 mg/syringe subcutaneously with prefilled syringe, one dose in 71 days

Interventions: intervention 1: Abatacept
Intervention descriptions: intervention 1: None

Protocol document: